4-Hydroxyphenylacetamide CAS 17194-82-0
  • 4-Hydroxyphenylacetamide CAS 17194-82-0 4-Hydroxyphenylacetamide CAS 17194-82-0

4-Hydroxyphenylacetamide CAS 17194-82-0

Praecipuum opificem sumus 4-Hydroxyphenylacetamidei CAS 17194-82-0 in China.4-Hydroxyphenylacetamide CAS 17194-82-0 praesto est in stipite ac celeriter tradi possumus. COA, MSDS et TDS de 4-Hydroxyphenylacetamide CAS 17194-82 -0.

Mitte Inquisitionem

depictio producti

Qualitas magnae 4-Hydroxyphenylacetamidei CAS 17194-82-0 multae applicationes occurrere possunt, si opus est, opportuna opera de 4-Hydroxyphenylacetamide CAS 17194-82-0 accipe, quaeso. Shandong Credite


4-Hydroxyphenylacetamide CAS 17194-82-0 chemical Specification

Product Name

1-Bromo-3,5-dichlorobenzene

Formulae

C6H3BrCl2

M. Pondus

225.9

CAS NO.

19752-55-7

quantitas

500KG


Items

Specification

Proventus

Aspectus

Conforms

Assay

≥ 98.0%

99.16%

Densitas

Liquescens punctum

CONCLUSIO

Effectus conformis vexillum


4-Hydroxyphenylacetamide CAS 17194-82-0 Chemical Properties

73-75 ° C punctum liquefactum (lit.).
232 ° c757mmhg fervens punctum (lit.)
Densitas 1.6351 (roughestimate)
Index refractivus 1.5700 (aestimatio)
Flash punctus 232 ° C
Signatus in siccis, roomtemperature
Chrysophyllum crystallinum
Color albus ut beige brunneis


4-Hydroxyphenylacetamide CAS 17194-82-0 Application

Productum hoc adhibetur ad synthesim aminopropranololum, quod genus est -obstructionum amet tractare hypertensionem, angina pectoris et arrhythmiam, et etiam efficacia ad glaucomas. Uti: Medicinae mediae et organici synthesis



Hot Tags: 4-Hydroxyphenylacetamide CAS 17194-82-0, Manufacturers, Suppliers, Tutus, Factory, In Stock, in Sinis, Sinis, Cheap, Discount, Quality, API, Investigationis et Progressus, Consuetudinis Synthesis

Related Categoria

Mitte Inquisitionem

Libenter placet, ut inquisitionem tuam in forma infra exhibeas. Respondebimus tibi in 24 horis.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept